US Stock MarketDetailed Quotes

IMRN Immuron

Watchlist
  • 2.520
  • -0.020-0.79%
Close May 3 16:00 ET
14.36MMarket Cap-5650P/E (TTM)

About Immuron Company

Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. Its proprietary technology is based on polyclonal immunoglobulins derived from engineered hyper-immune bovine colostrum. This technology can be used to target viruses or bacteria and neutralize the toxins they produce at mucosal surfaces. It operates through the Research and Development, and Hyperimmune Products segments. The Research and Development segment includes projects performed in Australia and United States. The Hyperimmune Products segment is composed of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994 and is headquartered in Carlton, Australia.

Company Profile

SymbolIMRN
Company NameImmuron
Listing DateJun 9, 2017
Issue Price10.00
Founded1994
CEOMr. Steven Lydeamore
MarketNASDAQ
Employees6
Securities TypeDR
ADS Ratio1.0 : 40.0
Fiscal Year Ends06-30
Address62 Lygon Street,Level 3
CityCarlton
ProvinceVictoria (VIC)
CountryAustralia
Zip Code3053
Phone61-3-9824-5254

Company Executives

  • Name
  • Position
  • Salary
  • Steven Lydeamore
  • Chief Executive Officer
  • 580.57K
  • Dr. Jerry Kanellos, PhD
  • Chief Operating Officer
  • 313.09K
  • Phillip A. Hains
  • Chief Financial Officer and Secretary
  • --
  • Flavio Palumbo
  • Chief Commercial Officer
  • 217.60K
  • Paul Brennan
  • Chairman of the Board
  • 132.17K
  • Stephen Anastasiou
  • Independent Director
  • 70.00K
  • Dr. Roger Aston
  • Independent Director
  • 116.03K
  • Professor Ravi Savarirayan
  • Independent Director
  • 70.00K
  • Daniel Pollock
  • Independent Director
  • 104.98K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg